ALM-401

ALM-401 is a first-in-class, next-generation bispecific antibody-drug conjugate (ADC) designed for the treatment of solid tumors characterized by dual expression of EGFR (epidermal growth factor receptor) and ROR1 (inactive tyrosine-protein kinase transmembrane receptor ROR1). Developed using a novel single-chain architecture, ALM-401 is approximately half the size of conventional ADCs, which enhances tumor penetration and manufacturing efficiency. Its pleiotropic mechanism includes direct tumor cell killing, blockade of EGFR-mediated signaling, and induction of bystander killing to increase therapeutic activity. Preclinical studies have shown durable and sustained tumor regressions in models such as non-small cell lung cancer (NSCLC), with improved efficacy compared to monospecific ROR1-targeting ADCs. The drug was developed through Almac Discovery’s proprietary OmniaScape platform in collaboration with Elasmogen Ltd., and has been licensed globally to Formosa Pharmaceuticals for further development and commercialization[1][2][3][7][9].

Other names

ALM 401ALM401ALM-401